NASDAQ:UPC Universe Pharmaceuticals (UPC) Stock Price, News & Analysis $3.39 -0.40 (-10.55%) Closing price 03:59 PM EasternExtended Trading$3.44 +0.05 (+1.62%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Universe Pharmaceuticals Stock (NASDAQ:UPC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get UPC alerts:Sign Up Key Stats Today's Range$3.31▼$3.7950-Day Range$2.54▼$12.1852-Week Range$2.00▼$17.96Volume43,299 shsAverage Volume4.16 million shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Universe Pharmaceuticals, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments. The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action. In parallel, Universe is exploring additional pipeline assets aimed at reducing post-operative scarring and controlling inflammation in anterior segment surgeries. Preclinical studies have demonstrated favorable pharmacokinetics and tissue penetration in animal models, supporting the potential for once-daily dosing regimens. Headquartered in the United Kingdom with a research subsidiary in the United States, Universe Pharmaceuticals maintains collaborations with academic institutions and contract development organizations to accelerate its drug development programs. The company is led by a management team with extensive experience in ophthalmology drug development and regulatory strategy, positioning it to advance its candidates through late-stage clinical trials and toward commercialization.AI Generated. May Contain Errors. Read More Universe Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreUPC MarketRank™: Universe Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingUniverse Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageUniverse Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Universe Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioUniverse Pharmaceuticals has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.44% of the float of Universe Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverUniverse Pharmaceuticals has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Universe Pharmaceuticals has recently decreased by 93.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUniverse Pharmaceuticals does not currently pay a dividend.Dividend GrowthUniverse Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentUniverse Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Universe Pharmaceuticals this week, compared to 1 article on an average week.Search Interest10 people have searched for UPC on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Universe Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders57.38% of the stock of Universe Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.18% of the stock of Universe Pharmaceuticals is held by institutions.Read more about Universe Pharmaceuticals' insider trading history. Receive UPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Universe Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UPC Stock News HeadlinesUniverse Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPCJuly 18, 2026 | benzinga.comUniverse Pharmaceuticals INC - Ordinary Shares - Class AJuly 17, 2026 | money.usnews.comUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days.July 24 at 1:00 AM | Freedom Financial (Ad)Universe Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:UPC | BenzingaJune 29, 2026 | benzinga.com4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesJune 29, 2026 | markets.businessinsider.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent PortfolioJune 27, 2026 | finanznachrichten.deUniverse Pharmaceuticals IncJune 26, 2026 | fool.comUPC stock surges 288% after hours — what’s driving the rally?June 26, 2026 | msn.comSee More Headlines UPC Stock Analysis - Frequently Asked Questions How have UPC shares performed this year? Universe Pharmaceuticals' stock was trading at $3.81 at the beginning of 2026. Since then, UPC stock has decreased by 11.0% and is now trading at $3.39. When did Universe Pharmaceuticals' stock split? Shares of Universe Pharmaceuticals reverse split before market open on Wednesday, November 13th 2024.The 1-15 reverse split was announced on Wednesday, November 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Universe Pharmaceuticals IPO? Universe Pharmaceuticals (UPC) raised $30 million in an IPO on Tuesday, March 23rd 2021. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Univest Securities, LLC served as the underwriter for the IPO. How do I buy shares of Universe Pharmaceuticals? Shares of UPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/24/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 11 days, UPC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPC Previous SymbolNYSE:UPC CIK1809616 WebN/A Phone86-0796-8403309FaxN/AEmployees220Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$17.86 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$99.64 per share Price / Book0.03Miscellaneous Outstanding Shares560,000Free Float240,000Market Cap$1.90 million OptionableN/A Beta1.46 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:UPC) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersThe number they’re trying to hide from youThe 10-year Treasury yield is nearing 4.4 percent, a level analyst Garrett Goggin says could force the Federal...Golden Portfolio | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredThe market told you. In writing. Early.Some trading losses are surprises. Others are scheduled months, even a year, in advance and published for free...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Universe Pharmaceuticals INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Universe Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
